Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C

Journal of Clinical Virology

Volumn 46, Issue 3, 2009, Pages 216-221

  Martinot Peignoux, Michelle ^a   Khiri, Hacène ^b   Leclere, Laurence ^a   Maylin, Sarah ^a   Marcellin, Patrick ^a   Halfon, Philippe ^b  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b Hospital Ambroise Pare   (France)

Author keywords

bDNA branched DNA; Chronic hepatitis C; EVR: early virological response; Pegylated interferon; Real time PCR; RVR: rapid virological response; TMA: transcription mediated amplification

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 72149131752     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.08.011     Document Type: Article

References (47)

1. Maylin S., Martinot-Peignoux M., Moucari R., Boyer N., Ripault M.P., Cazals-Hatem D., et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135 September (3) (2008) 821-829
2. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 September 22 (9286) (2001) 958-965
3. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 September 26 (13) (2002) 975-982
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 March 2 (5) (2004) 346-355
5. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36(November (5 Suppl. 1)):S3-20.
6. Marcellin P., Pouteau M., Martinot-Peignoux M., Degos F., Duchatelle V., Boyer N., et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109 July (1) (1995) 156-165
7. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22 October (4 Pt 1) (1995) 1050-1056
8. Martinot-Peignoux M., Boyer N., Pouteau M., Castelnau C., Giuily N., Duchatelle V., et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 29 August (2) (1998) 214-223
9. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 March (3) (2003) 600-609
10. von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 August (2) (2005) 522-527
11. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 January (1) (2006) 97-103
12. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 May (5) (2006) 954-960
13. Davis G.L. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36 November (5 Suppl. 1) (2002) S145-S151
14. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 September (3) (2003) 645-652
15. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 September (3) (2005) 425-433
16. Dalgard O., Bjoro K., Hellum K.B., Myrvang B., Ritland S., Skaug K., et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40 December (6) (2004) 1260-1265
17. Carlsson T., Reichard O., Norkrans G., Blackberg J., Sangfelt P., Wallmark E., et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 12 September (5) (2005) 473-480
18. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 June 23 (25) (2005) 2609-2617
19. Martinot-Peignoux M., Comanor L., Minor J.M., Ripault M.P., Pham B.N., Boyer N., et al. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. J Viral Hepat 13 October (10) (2006) 701-707
20. Martinez-Bauer E., Crespo J., Romero-Gomez M., Moreno-Otero R., Sola R., Tesei N., et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 43 January (1) (2006) 72-80
21. Sanchez-Tapias J.M., Diago M., Escartin P., Enriquez J., Romero-Gomez M., Barcena R., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 August (2) (2006) 451-460
22. Moucari R., Ripault M.P., Oules V., Martinot-Peignoux M., Asselah T., Boyer N., et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 46 April (4) (2007) 596-604
23. Martinot-Peignoux M., Maylin S., Moucari R., Ripault M.P., Boyer N., and Cardoso A.C. Virological response at 4 week to predict outcome of hepatitis C treatment with peginterferon and ribavirin. Antivir Ther 14 4 (2009) 501-511
24. Elbeik T., Surtihadi J., Destree M., Gorlin J., Holodniy M., Jortani S.A., et al. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV-RNA 3.0 assay (bDNA). J Clin Microbiol 42 February (2) (2004) 563-569
25. Gerken G., Rothaar T., Rumi M.G., Soffredini R., Trippler M., Blunk M.J., et al. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 38 June (6) (2000) 2210-2214
26. Colucci G., Ferguson J., Harkleroad C., Lee S., Romo D., Soviero S., et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 45 November (11) (2007) 3595-3600
27. Michelin B.D., Muller Z., Stelzl E., Marth E., and Kessler H.H. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 38 February (2) (2007) 96-100
28. Comanor L., Anderson F., Ghany M., Perrillo R., Heathcote E.J., Sherlock C., et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV-RNA at end of treatment. Am J Gastroenterol 96 October (10) (2001) 2968-2972
29. Bouchardeau F., Cantaloube J.F., Chevaliez S., Portal C., Razer A., Lefrere J.J., et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45 April (4) (2007) 1140-1145
30. Sarrazin C., Gartner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44 March (3) (2006) 729-737
31. Tuaillon E., Mondain A.M., Ottomani L., Roudiere L., Perney P., Picot M.C., et al. Impact of hepatitis C virus (HCV) genotypes on quantification of HCV-RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV realtime assay and VERSANT HCV-RNA assay. J Clin Microbiol 45 September (9) (2007) 3077-3081
32. Vermehren J., Kau A., Gartner B.C., Gobel R., Zeuzem S., and Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV-RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46 December (12) (2008) 3880-3891
33. Saldanha J., Heath A., Lelie N., Pisani G., Nubling M., and Yu M. Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang 78 4 (2000) 217-224
34. Laperche S., Bouchardeau F., Thibault V., Pozzetto B., Vallet S., Rosenberg A.R., et al. Multicenter trials need to use the same assay for hepatitis C virus viral load determination. J Clin Microbiol 45 November (11) (2007) 3788-3790
35. Halfon P., Bourliere M., Penaranda G., Khiri H., and Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 44 July (7) (2006) 2507-2511
36. Halfon P., Penaranda G., Bourliere M., Khiri H., Masseyeff M.F., and Ouzan D. Assessment of early virological response to antiviral therapy by comparing four assays for HCV-RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. J Med Virol 78 February (2) (2006) 208-215
37. Chevaliez S., Bouvier-Alias M., Brillet R., and Pawlotsky J.M. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46 July (1) (2007) 22-31
38. Matsuura K., Tanaka Y., Hasegawa I., Ohno T., Tokuda H., Kurbanov F., et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol 47 February (2) (2009) 385-389
39. Sarrazin C., Teuber G., Kokka R., Rabenau H., and Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 32 October (4 Pt 1) (2000) 818-823
40. Gerotto M., Dal Pero F., Bortoletto G., Ferrari A., Pistis R., Sebastiani G., et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 44 January (1) (2006) 83-87
41. Morishima C., Morgan T.R., Everhart J.E., Wright E.C., Shiffman M.L., Everson G.T., et al. HCV-RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 44 August (2) (2006) 360-367
42. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 July 12 (2) (2007) 124-134
43. Dalgard O., Bjoro K., Ring-Larsen H., Bjornsson E., Holberg-Petersen M., Skovlund E., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 January (1) (2008) 35-42
44. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 April (4) (2006) 1086-1097
45. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 December (6) (2007) 1688-1694
46. Marcellin P., Heathcote E.J., and Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?. J Hepatol 47 October (4) (2007) 580-587
47. Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carretta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47 January (1) (2008) 43-50